BioStem Appoints Katherine Gorrell as Chief Legal & Compliance Officer, Signaling Growth and Nasdaq Uplisting Ambitions
BioStem Technologies strengthens its leadership by appointing Katherine Gorrell, a seasoned legal and compliance executive, to oversee governance and regulatory strategy as the company pursues a Nasdaq uplisting.
BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, has appointed Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. The move underscores the company’s focus on strengthening governance and compliance as it prepares for a Nasdaq uplisting, Chairman and CEO Jason Matuszewski said.
Gorrell brings two decades of experience advising hospital systems and health technology companies on health law, regulatory compliance, transactional matters, and risk management. In her new role, she will oversee BioStem’s legal and compliance functions and integrate Medical Affairs into the company’s compliance framework, according to the announcement.
“Katherine is a key addition to BioStem as we implement our next phase of growth,” Matuszewski said. “Her leadership will support our continued scaling while reinforcing our strong foundation of integrity and compliance, especially as we progress toward a Nasdaq uplisting.”
Most recently, Gorrell served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, Florida, where she was a member of the executive team. She previously held roles as General Counsel and Compliance Officer at AdvancedMD, a national healthcare IT company, and advised on operational and strategic matters at Intermountain Healthcare and Providence Health & Services/Swedish Health Services. She holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law.
“BioStem is at a pivotal time in its growth and evolution. I look forward to working with the leadership team and board to support sustainable growth, strengthen governance, and ensure our legal, compliance, and medical affairs functions continue to evolve with the business,” Gorrell said.
The appointment comes as BioStem, which develops and commercializes advanced allograft solutions using proprietary technologies like BioRetain®, CryoTek®, and SteriTek®, expands its portfolio and national commercial footprint. The company’s quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Its product lines include Neox®, Clarix®, VENDAJE®, and American Amnion™.
BioStem’s pursuit of a Nasdaq uplisting signals a desire to attract a broader investor base and increase liquidity. According to the company’s newsroom at https://tinyurl.com/bsemnewsroom, the latest updates on $BSEM are available there. The company also maintains a presence on social media platforms like X and LinkedIn.
Gorrell’s appointment is effective immediately, and she will play a central role in enterprise governance as BioStem navigates its next growth phase, including potential regulatory and compliance challenges associated with a major exchange listing.